Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC.

Naoko Katsurada Motoko TachiharaYukihisa HatakeyamaKiyoko KoyamaMasako YumuraTatsunori Kiriu Ryota DokuniDaisuke HazamaShuntaro TokunagaDaisuke TamuraKyosuke Nakata Masatsugu Yamamoto Hiroshi KamiryoKazuyuki KobayashiYugo TanakaYoshimasa ManiwaYoshihiro Nishimura

Published in: Cancer management and research (2020)

The completion rate for CBDCA plus nab-PTX as adjuvant chemotherapy for CDDP-unfit NSCLC patients did not reach treatment feasibility. Further dose modifications may be required in future studies.

Keyphrases

advanced non small cell lung cancer
small cell lung cancer
end stage renal disease
prognostic factors
ejection fraction
newly diagnosed
chronic kidney disease
lymph node
epidermal growth factor receptor
squamous cell carcinoma
patient reported outcomes
radiation therapy
rectal cancer
patient reported